EGFR and non-small cell lung carcinoma: Finally, more and more EGFR‐mutated, advanced NSCLC patients receive osimertinib as first‐line treatment, whether the antiangiogenic‐based therapy is also applicable to first‐line osimertinib resistant patients remains unclear, which needs to be further explored.